This study also shows that polymorphic variation in CYP1A1, GSTP1 and GSTM1 null genotype might influence the molecular response and treatment outcome in CML patients. The gene discussed is GSTM1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.